Richard Milazzo
Internal Medicine · Dunkirk, NYNPI 1487605150
Payments from drug & device makers
Across 155 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$435
- Novo Nordisk$318
- Lilly USA, LLC$223
- AbbVie$216
- GSK$144
- AstraZeneca$132
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,51998%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $435 |
| Novo Nordisk | 20 | $318 |
| Lilly USA, LLC | 15 | $223 |
| AbbVie(2 entities) | 10 | $216 |
| GSK | 10 | $144 |
| AstraZeneca | 9 | $132 |
| Boehringer Ingelheim | 7 | $125 |
| Astellas Pharma US Inc | 7 | $124 |
| Johnson & Johnson | 8 | $123 |
| Abbott | 5 | $101 |
| Amarin Pharma, Inc. | 3 | $62 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Bayer | 3 | $56 |
| Merck | 3 | $53 |
| Exact Sciences | 2 | $49 |
| Grifols USA, LLC | 3 | $49 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Pfizer | 3 | $38 |
| Novartis | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Mannkind Corporation | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Sanofi | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$2,563 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 28 | $27,086 |
| JardianceEmpagliflozin | 18 | $12,288 |
| Memantine Hcl ErMemantine Hcl | 18 | $2,723 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,680 |
| Potassium Chloride | 14 | $856 |
| Atorvastatin Calcium | 65 | $700 |
| Rosuvastatin Calcium | 16 | $630 |
| Levothyroxine Sodium | 48 | $623 |
| Pantoprazole Sodium | 40 | $567 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $431 |
| Sertraline Hcl | 34 | $420 |
| Donepezil Hcl | 18 | $395 |
| Metoprolol Succinate | 16 | $357 |
| Ibuprofen | 19 | $343 |
| Amlodipine Besylate | 49 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $38 | $27,08628 claims |
| Boehringer IngelheimJardiance | $125 | $12,28818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Dunkirk
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.